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Summary The distribution and localization of NCA and carcinoembryonic antigen CEA in cells of different
types of myelogenous leukaemias (acute myelogenous leukaemia - AML; chronic granulocytic leukaemia -
CGL; CGL in myeloblastic crisis - CGL-BC) was studied using the immunofluorescence test. Discontinuous
density-gradient centrifugation was used to separate myeloid cells into fractions containing granulocytes in
individual stages of maturation. Serum NCA and CEA levels were estimated in parallel. It was established
that: (a) AML blasts without maturation (MO type) and monoblasts did not synthesize NCA; (b) individual
blasts of AML with features of maturation (MI, M2 types) and some myeloblasts of CGL-BC exhibited a
limited ability to express cytoplasmic NCA; (c) the number of NCA-containing cells increased in the more
mature granulocyte fractions isolated on Ficoll-Hypaque density-gradients; (d) myelocytic NCA is immuno-
logically related to NCA isolated from lung tissue and (e) CEA is undetectable in the myelocytic cell series.
The non-specific cross-reacting antigen (NCA)
shares antigenic determinants with CEA but also
bears a specific determinant not present on CEA
because anti-NCA sera absorbed by CEA continue
to precipitate NCA (Mach & Pusztaszeri, 1972; von
Kleist et al., 1972; Bordes et al., 1975; Chavanel et
al., 1983; Rogers, 1983). In the last decade NCA
has also been found in normal polymorphs and
macrophages and then in pathological cells in
patients with myelocytic leukaemias (Bordes et al.,
1975; Burtin et al., 1975, 1979; Heumann et al.,
1979; Wahren et al., 1979, 1980; Burtin et al., 1980;
Pattengale et al., 1980). It is generally agreed that
NCA is a differentiation marker of the myelocytic
cell series. However, there is controversy concerning
the initial stages of NCA production during
myelocytic cell maturation (Burtin et al., 1979;
Heumann et al., 1979; Burtin et al., 1980; Wahren
et al., 1980).
Using immune sera against CEA and NCA
previously characterized (Hartozifiska et al., 1983;
Kula et al., 1983) we have studied: (i) the
distribution and localization of NCA and CEA in
cells of different types of leukaemias and normal
donors; (ii) the presence of NCA in individual
stages of granulocyte differentiation in chronic
(CGL) and acute myeloid leukaemias (AML) and
(iii) CEA and NCA serum levels in patients with
leukaemias and control donors.
Materials and methods
Patients
Seventeen AML cases were studied, which were
classified according to the proposal of the FAB-
Cooperative Group (Bennet et al., 1976). Fourteen
cases of CGL were also investigated, 5 of these
subjects were in myeloblastic crisis (CGL-BC) and
formed a separate group. The diagnosis was
established by standard morphological and cyto-
chemical criteria. The cytochemical routine
determinations included the PAS reaction, lipid
staining, activity of acid and alkaline phosphatases,
a-naphthyl acetate esterase and peroxidase. All
immunological tests were performed before
initiating treatment and only two patients with
CGL occasionally received small doses of
busulphan. In 5 cases of AML, 4 of CGL, and 3 of
CGL-BC we were able to perform simultaneously
the estimations of NCA content in bone marrow
cells. Control studies were performed on cells of 6
ALL patients and on granulocytes of 6 normal
donors.
Immune sera
The specific anti-CEA and anti-NCA sera were
prepared by immunizing goats with purified CEA
(Zawadzka et al., 1979) or NCA (Krop-Watorek et
al., 1983) as described previously (Harkozinska et
al., 1983; Kula et al., 1983). Both antisera used in
the IF tests were additionally absorbed on the
columns prepared by coupling purified CEA or
NCA to CNBr-activated Sepharose 4B to remove
NCA- or CEA-cross active antibodies respectively.
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Cell separation
To separate the myelocytic cells into fractions
containing granulocytes in individual stages of
maturation discontinuous density-gradient
centrifugation was applied (Ficoll-Hypaque 1.05-
1.12 gml -1) as earlier described in detail
(Harlozifiska et al., 1982). The cell layers
concentrated at each density interface were
aspirated, washed with PBS, and counted. This
method of cell separation was applied for all CGL
but only in 2 AML cases. Remaining leukaemia
cells from 15 AML patients were isolated in 3%
dextran T500 (Pharmacia, Sweden) because the
WBC count was low and the peripheral blood or
bone marrow cells of these patients contained
>65% blasts. The cells isolated on dextran and the
cells of each density layer were checked for the
presence of NCA and CEA by IF and stained in
parallel with Wright-Giemsa to determine
differential morphology.
Immunological methods
Smears of dextran isolates and the cells
concentrated in each density gradient were used in
the indirect IF test. All smears were fixed for
10min in a mixture of ethanol and acetic acid
(95:5) and then incubated with specific goat anti-
NCA or anti-CEA serum diluted 1/80. After the
unbound antibodies had been washed out, the cell
monolayers were stained with fluorescein isothio-
cyanate (FITC)-labelled rabbit anti-goat globulin
(Miles Lab. Ltd., Slough, England) preabsorbed
with mouse liver powder and lyophilized perchloric
acid (PCA) extract of normal spleen. The smears
were finally washed in PBS and mounted in a
solution of glycerol and PBS (1:1) and evaluated in
an Opton type III Photomicroscope using incident-
light excitation. The staining reactions were
interpreted with reference to the control smears
with: (a) PBS, (b) normal goat serum, (c) anti-NCA
serum absorbed with PCA extracts of normal lung
or spleen tissues and (d) anti-NCA serum
unabsorbed with CEA.
Serum NCA levels were assayed by radio-
immunoassay (Gadler et al., 1978).
The double diffusion test was performed in 1%
agarose gel with PCA extracts of normal lung,
spleen, and CGL cells at concentrations of 10-
50 mgml - 1 and with CEA and NCA at a
concentration of 0.1 mgml-1. To block the activity
of anti-NCA serum with PCA extracts of normal
tissues or CGL-PCA extract, an additional
absorption with the definitive antigen was carried
out on an agarose plate (Ibrahim et al., 1979).
Results
The results of NCA determinations in different
types of AML are summarized in Table I. AML
(blasts) without maturation (MO) were NCA-
negative. The number of NCA-containing cells
increased beginning with individual blasts of Ml
and M2 AML types (Figure la). The myelomono-
cytic leukaemias (M4) showed a low percentage of
positively reacting cells but their precise
morphological classification was difficult. In mono-
blastic leukaemias (M5) all blasts were negative
(Figure lb) and in one erythroleukaemia case the
percentage if fluorescence-positive cells was similar
to the number of mature granulocytes. The
comparison of NCA expression in identically
studied preparations of bone marrow cells from 1
case of AML (type M2), 2 myelomonocytic
leukaemias (M4), and 2 monocytic leukaemias (M5)
showed a similar distribution of this antigen to the
respective fractions of peripheral blood cells. In
Table I NCA content in peripheral blood cells and serum of AML patients
IF test
Wright-Giemsa morphologyb NCAa
(mean % and range) cells NCA serum
No. of (mean % (mean level in
Leukaemias patients Blasts PMM Mono Lym and range) ngml-1)
AML classificationa
MO (without maturation) 2 81 (80-82) 2 (0-4) 17 (16-18) 0.5 (0.0-1.0) 5.0
Ml (weak maturation) 2 88 (86-90) 4 (3-5) 8 (7-9) 6.0 (2.0-10.0) 3.0
M2 (distinct maturation) 4 81 (67-91) 9 (0-12) 10 (0-15) 13.0 (3.5-20.5) 0.0
M4 (myelomonocytic) 3 87 (60-94) 9 (6-22) 4 (0-18) 5.0 (0.0-9.0) 0.0
M5 (monoblastic) 5 77 (66-98) 6 (0-11) 6 (0-21) 11 (0-23) 4.0 (0.0-13.0) 7.0
M6 (erythroleukaemia) 1 19 81 70.0 30.0
ALL 6 74 (70-90) 6 (0-11) 20 (3-30) 0.0 7.5
aAccording to FAB Cooperative Group.
bBlasts =myeloblasts; PMN =polymorphononuclear neutrophils; Mono =monocytes; Lyma lymphocytes.NCA IN MYELOCYTIC CELLS 373
(a) (b)
(c) (d)
(e) (f)
(g)
Figure 1 (a) AML type M2 cells treated with anti-NCA serum showing intense cytoplasmic fluorescence of
an individual blast. (b) AML type M5 cells with predominance of monoblasts treated with anti-NCA serum.
All cells are negative. (c) CGL-BC cells isolated in 1.05gml- fraction treated with anti-NCA serum showing
cytoplasmic fluorescence of a single blast. (d) CGL cells isolated in 1.07gml-1 fraction treated with anti-
NCA serum showing intense cytoplasmic fluorescence of majority myelocytes and metamyelocytes. (e) CGL
cells isolated in 1.09gml- fraction treated with anti-NCA serum showing cytoplasmic fluorescence of
majority bands and PMN neutrophils. (f) Normal granulocytes isolated in 1.15gml-l fraction treated with
anti-NCA serum showing cytoplasmic fluorescence. (g) CGL cells isolated in dextran and treated with anti-
CEA serum showing negative fluorescence.374 A. NOWOROLSKA et al.
these cases morphological pictures of blood and
bone marrow cells stained by Wright-Giemsa were
also similar.
The analysis of NCA presence in peripheral
blood and bone marrow cells of patients with
CGL-BC and CGL isolated on discontinuous
density-gradient centrifugation showed that
expression of this antigen increased with maturity
of the cells in the denser layers (Tables II & III).
The Ficoll-Hypaque density-gradient procedure
permitted the separation of myeloid cells according
to the degree of morphological maturation so that
young forms of granulocytes focused in low-density
fractions, whereas polymorphonuclear neutrophils
were confined to high-density fractions. This
method yielded sufficient immature cells for NCA
content analysis and facilitated comparison of the
presence of this antigen in different maturation
forms of granulocytes both in CGL and in CGL-
BC patients (Table III).
In the individual case presented (Table II) the
blood leukocytes concentrated in the low density
fractions of Ficoll-Hypaque contained more
detectable NCA than the bone marrow cell
fractions studied in parallel. Morphologically, the
bone marrow cells of this patient showed distinct
cellular rejuvenation in comparison to blood cell
preparations.
Table IV shows the percentage of myeloid cells
representing NCA + cells in individual stages of
granulocyte differentiation (CGL-BC case) in
comparison with their morphological picture after
Wright-Giemsa staining. The detailed analysis of
preparations containing early forms of granulocytes
focused in fractions 1.05-1.07 gml - 1 and com-
parison with the fluorescence test on the same cells
observed in phase-contrast showed that some blasts
exhibited distinct cytoplasmic NCA-dependent
staining. This was usually seen in about 10-20% of
total blasts present in preparation (Figure Ic).
Many pathological myelocytes and metamyelocytes
were NCA-positive (40-70%) but their number and
fluorescence intensity varied from one case to
another (Figure Id). About 80-90% of mature
neutrophils concentrated mainly in fractions 1.09-
1.105gml-1 were NCA positive (Figure le)
analogous to the finding for the neutrophils of
healthy persons (Table III, Figure If). Interestingly,
the percentage of NCA positive cells increased in
the more dense Ficoll-Hypaque fractions even
within the same morphological forms of
granulocytes. By contrast, ALL peripheral blood
lymphoblasts were always negative (Table I).
Anti-CEA serum did not stain cells in any
fractions of CGL-BC and CGL cells (Figure Ig).
Similarly the lymphoid and monocytic cell series
were CEA negative.
Serum NCA levels in patients with AML and
ALL usually were very low or indetectable (Table
I) in comparison to levels of 30ngml-1 in the sera
of normal donors (Table III). In CGL patients the
level of circulating NCA was always elevated to a
mean value of 140 ngml- 1, and in one case
exceeded 400 ngml- 1. The serum NCA values in
patients with myeloblastic crisis of CGL usually
amounted lOOngml-1 (Table III). CEA in plasma
was within the normal range (0-7ngml-1) in all
studied patients.
Table II NCA and CEA content in peripheral blood and bone marrow cells
separated by density gradient centrifugation in a patient with CGL
Wright-Giemsa morphologya (%)
Density IF test Serum
layer Blasts Myel Band CEA+ NCA+ level
Material (gml 1) Pro Mta PMN Lym cells (%) (ngml 1)
Blood Dextran 5 25 66 4 0.0 84.0
1.06 1 34 51 14 0.0 52.0 NCA-410.0
1.07 2 57 41 0 0.0 90.0 CEA- 2.0
1.09 0 16 84 0 0.0 96.0
1.105 0 23 77 0 0.0 91.0
Bone marrow Dextran 2 48 50 0 0.0 82.0
1.05 3 78 16 3 0.0 9.0
1.06 2 69 29 0 0.0 28.0
1.07 0 73 27 0 0.0 68.0
1.08 1 70 29 0 0.0 74.0
1.105 0 50 48 2 0.0 78.0
aPro =promyelocytes; Myel=myelocytes; Mta=metamyelocytes; Band=band
forms.
For other abbreviations see legend to Table I.NCA IN MYELOCYTIC CELLS 375
The reactivity of anti-NCA serum with PCA
extract of CGL-cells,NCA, and CEA standards
compared by double immunodiffusion showed
identity or immunological relationship of the NCA
extracted from leukaemic granulocytes and NCA
earlier isolated from normal lung tissues (Figure 2).
Additional absorption on an agarose plate of anti-
NCA serum with PCA extracts of normal lung or
spleen tissues removed the reactivity of this anti-
serum not only with the extracts but also with CGL
cells. Removing the activity with the the NCA
standard was dependent on the concentration of
normal tissue PCA extracts used in additional
absorptions as an NCA source.
Figure 2 Double immunodiffusion of anti-NCA
serum with 1-NCA, 2-PCA-CGL, 3-CEA.
Discussion
These results demonstrate that: (i) AML blasts
lacking the ability to mature (MO type) and mono-
blasts did not contain NCA; (ii) individual AML
blasts with features of maturation (Ml, M2 types)
and some blasts from myeloblastic crisis of CGL
showed a limited expression of cytoplasmic NCA;
(iii) the number of NCA containing cells increased
as the more mature granulocyte fractions were
isolated on Ficoll-Hypaque density-gradients; and
(iv) myelocytic NCA is immunologically related if
not identical with NCA isolated from lung tissue.
The stage in which NCA appears in the course of
granulocyte differentiation is interesting mainly in
relation to understanding the biological role of this
glycoprotein. Our studies indicated that NCA
appears early in the differentiation process of the
myeloid cell series and is detectable in some
differentiated myeloblasts (M1, M2 type
leukaemias). These observations are concordant
with earlier data of Burtin et al. (1979, 1980)
suggesting that NCA can play a role in protection
of granulocytic cells against their own enzymes.
Other authors (Heumann et al., 1979; Wahren et
al., 1979, 1980) were not able to detect NCA in
myeloblasts and believed that it is a marker of
more mature myeloid cells. Application of density-
gradient centrifugation to separate granulocytes
permitted the study of NCA distribution in
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Table IV Percentage of NCA+ cells in peripheral blood cells separated by density-gradient centrifugation in
a patient with CGL-BC
Wright-Giemsa morphology (%) IF test (%)
Density layer Blasts Myel Band Mta
(gml-1) Pro Mta PMN Lym NCA+ Blasts NCA+ Myel NCA+ Band NCA+ PMN
1.05 33 51 16 0 7 46 0 0
1.06 22 46 32 0 14 58 64 78
1.07 11 39 48 2 22 72 64 70
1.08 2 16 82 0 0 NDa 75 72
1.09 0 14 86 0 0 0 83 98
aND =not done.
For other abbreviations see legends to Tables I and II.
individual stages of granulocyte differentiation and
comparison of IF results with phase-contrast
appearances permitted an estimate of the number
and type of NCA positively reacting cells in
different fractions. It is worth emphasizing that
independently of the increasing NCA content in
morphologically more mature granulocytes, even
myeloblasts and myelocytes focused in less dense
Ficoll-Hypaque layers expressed a lower percentage
of NCA positive cells than the same cellular forms
from denser layers. It is probable that NCA+ and
NCA- myeloblasts and myelocytes could represent
slight differences in maturation stage and density of
these forms ofgranulocytes.
The mean NCA serum levels in CGLs were
higher than in normal subjects and similar to those
estimated by Frenoy et al. (1982). In our studies we
noted large variations of serum NCA levels in
individual cases. It is possible that values of
circulating NCA in individual patients are
dependent rather upon the number of NCA
containing cells than on WBC count. AML patients
with a small percentage of positively reacting cells
had low serum NCA level, even when their WBC
count was high. It could also be explained by the
low rate of NCA synthesis in the immature
leukaemic cells (Frenoy et al., t982). On the other
hand, the ability to secrete NCA into the blood
circulation from the myeloid cell series may play an
important role in the regulation of the NCA serum
level.
According to some authors (Bordes et al., 1975;
Heumann et al., 1979; Nap et al., 1983) myelocytic
NCA is immunologically identi'cal to NCA isolated
from normal lungs. Our preliminary results showed
an immunological relationship betweeii lung and
myelocytic NCA. However, detailed immuno-
precipitation studies revealed some antigenic hetero-
geneity in NCA molecules since the precipitation
lines with anti-NCA serum given by standard NCA
and individual extracts of normal lung, spleen, or
CGL cells, did not always show complete identity
(unpublished data). In our opinion this interesting
problem demands more detailed study, especially
since recently Chavanel et al. (1983) revealed the
existence of at least two epitopes on the specific
moiety of NCA.
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